Literature DB >> 11118287

PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver.

A Hermanowski-Vosatka1, D Gerhold, S S Mundt, V A Loving, M Lu, Y Chen, A Elbrecht, M Wu, T Doebber, L Kelly, D Milot, Q Guo, P R Wang, M Ippolito, Y S Chao, S D Wright, R Thieringer.   

Abstract

11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) is an enzyme that converts cortisone to the active glucocorticoid, cortisol. Cortisol-cortisone interconversion plays a key role in the regulation of glucose metabolism, since mice deficient in 11betaHSD1 are resistant to diet-induced hyperglycemia. Peroxisome proliferator activator receptors (PPAR) are key regulators of glucose and lipid homeostasis. We observed a striking downregulation of murine hepatic 11betaHSD1 expression and activity after chronic treatment of wild-type mice with PPARalpha agonists, while 11betaHSD1 in the livers of PPARalpha knockout mice, or in mice treated for only 7 h with PPARalpha agonists, was unaltered. Our results are the first to show PPARalpha agonists can affect glucocorticoid metabolism in the liver by altering 11betaHSD1 expression after chronic treatment. Regulation of active glucocorticoid levels in the liver by PPARalpha agonists may in turn affect glucose metabolism, consistent with reports of their antidiabetic effects. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118287     DOI: 10.1006/bbrc.2000.3966

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

Review 1.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 2.  Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.

Authors:  P Putignano; F Pecori Giraldi; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 3.  Signalling mechanisms linking hepatic glucose and lipid metabolism.

Authors:  M O Weickert; A F H Pfeiffer
Journal:  Diabetologia       Date:  2006-05-23       Impact factor: 10.122

Review 4.  11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.

Authors:  Karen E Chapman; Jonathan R Seckl
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

Review 5.  The biological actions of dehydroepiandrosterone involves multiple receptors.

Authors:  Stephanie J Webb; Thomas E Geoghegan; Russell A Prough; Kristy K Michael Miller
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

Review 6.  Nuclear receptor crosstalk - defining the mechanisms for therapeutic innovation.

Authors:  Karolien De Bosscher; Sofie J Desmet; Dorien Clarisse; Eva Estébanez-Perpiña; Luc Brunsveld
Journal:  Nat Rev Endocrinol       Date:  2020-04-17       Impact factor: 43.330

Review 7.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

Review 8.  11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.

Authors:  T M Stulnig; W Waldhäusl
Journal:  Diabetologia       Date:  2003-12-03       Impact factor: 10.122

9.  Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.

Authors:  Janice M Paterson; Nicholas M Morton; Catherine Fievet; Christopher J Kenyon; Megan C Holmes; Bart Staels; Jonathan R Seckl; John J Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

10.  Effects of proportions of dietary macronutrients on glucocorticoid metabolism in diet-induced obesity in rats.

Authors:  Roland H Stimson; Gerald E Lobley; Ioanna Maraki; Nicholas M Morton; Ruth Andrew; Brian R Walker
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.